As described recently (32, 33), we observed that neutralization-escape rVSV-SARS2 mutants of the NTD-targeting MAb were resistant to neutralization by COVID-19 convalescent donor sera, suggesting that natural variants in the NTD could, at least in part, escape the antibody response. This evidence concerns the gene SARS2 and COVID-19.